Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma
Zhi‐Yuan Zhou(Tsinghua University), Mingzhi Zhang(Chinese Academy of Sciences), Xin Li(China Medical University), Xinhua Wang(Zhengzhou University), Lei Zhang(Union Hospital), Xudong Zhang(Southwest University of Science and Technology), Zhenchang Sun(First Affiliated Hospital of Zhengzhou University), Ling Li(Johns Hopkins University), Xiaorui Fu(First Affiliated Hospital of Zhengzhou University), Zhaoming Li(First Affiliated Hospital of Zhengzhou University)
Cited by 19
Related Papers
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
|Frontiers in Immunology|2017|296
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
|Journal of Hematology & Oncology|2016|250
Reversing insufficient photothermal therapy-induced tumor relapse and metastasis by regulating cancer-associated fibroblasts
|Nature Communications|2022|247
Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study
|The Lancet Infectious Diseases|2015|231
Altermagnets as a new class of functional materials
|Nature Reviews Materials|2025|200